Longevity Services & Practice Library
Every article, presentation, spotlight, and news item we've tagged to Longevity Services & Practice.
Showing 49–72 of 235
Fountain Life adds APEX to premium longevity program
Fountain Life launched APEX, a year-long premium membership that integrates full-body diagnostic screening with functional movement assessment and VO₂ max testing to shift from episodic health snapshots to continuous, performance-focused monitoring. This model addresses a gap in longevity medicine: most preventive programs measure biomarkers and imaging but neglect movement quality and cardiorespiratory capacity—the actual mechanics of aging and functional independence.
CMS, FDA Set Aging Biomarker Requirements for Longevity Coverage
The first major US longevity policy summit convened federal regulators, researchers, and lawmakers to address the regulatory and funding barriers slowing longevity science translation. The convergence signals political recognition that healthspan improvement represents a national priority rather than a niche scientific interest.
Vitalist Bay 2026 Returns to Berkeley May 14–17
Vitalist Bay 2026, the world's largest longevity conference, returns to Berkeley May 14–17 with over 60 speakers and workshops spanning aging biology, AI, biotech translation, and investment. The event consolidates leading researchers, entrepreneurs, clinicians, and investors into a four-day intensive focused on accelerating the scientific and commercial infrastructure around human lifespan extension.
Education platform targets longevity knowledge gap
A curated education marketplace has launched to address the fragmentation in longevity learning, creating a vetted platform for clinicians, practitioners, and consumers to access high-quality programs that bridge scientific discovery and clinical practice. The platform recognizes that rapid advancement in longevity science has outpaced the development of standardized, accessible training infrastructure.
Longevity Show launches 2026 pitch competition
The Longevity Show launches a 2026 pitch competition for consumer-ready healthspan startups, targeting the critical gap between laboratory discovery and real-world implementation. The competition emphasizes clinical plausibility and measurable impact over marketing hype, reflecting the sector's maturation toward systems-based, scalable prevention rather than isolated interventions.
Abu Dhabi opens a real-world test lab for longevity
Abu Dhabi is establishing an integrated health infrastructure that combines clinical records, genetic data, and continuous wearable monitoring into a real-time evidence system designed to shift healthcare from reactive treatment to predictive intervention. This represents a systematic approach to testing longevity interventions within functioning health systems rather than isolated research environments.
Longevity Sector Shifts to Systems-Based Healthspan Infrastructure
Five finalists selected for The Longevity Show's inaugural pitch competition represent a conceptual shift in the longevity sector—from single-intervention therapies to integrated systems spanning therapeutics, nutrition, microbiome science, and healthcare access. The cohort signals movement toward infrastructure that supports healthspan across diverse populations and geographies.
A Multidomain Lifestyle Intervention Is Associated With Improved Functional Trajectories and Favorable Changes in Epigenetic Aging Markers in Frail Older Adults: A Randomized Controlled Trial
A 6-month multidomain lifestyle intervention combining nutritional support and supervised exercise slowed epigenetic aging markers and improved physical function in frail adults over 80, with measurable reductions in biological aging indicators. The findings suggest that coordinated lifestyle strategies can alter the trajectory of age-related decline at the molecular level, not merely at the symptomatic level.
Longevity law finds its footing
As longevity ventures mature from research-driven enterprises to scalable commercial platforms, specialized legal frameworks become essential infrastructure. The establishment of dedicated longevity legal practices signals that regulatory clarity and compliant business model design are now rate-limiting factors for sector growth, not biology itself.
Longevity Show Expands to New York: Bridging Science and Practice
The Longevity Show, a science-focused conference that attracted 3,000+ visitors to London in its inaugural event, will expand to New York in May 2027. The event bridges academic research, clinical practice, and consumer health engagement without compromising scientific rigor—a structural shift that reflects growing mainstream acceptance of longevity science as evidence-based practice rather than wellness marketing.
#383 ‒ AMA #81: Biological aging tests, longevity training, emerging therapies, GLP-1 RAs, sun exposure, and more
This AMA addresses multiple longevity domains: biological aging biomarkers, exercise protocols for longevity, emerging therapeutic approaches, GLP-1 receptor agonists, and sun exposure risk-benefit profiles. The discussion emphasizes that evidence-based interpretation of these tools requires distinguishing between mechanistic plausibility and demonstrated clinical outcomes.
Longevity market poised for growth as AI and genomics accelerate developments
The global longevity market is projected to exceed $740 billion by 2026, driven by a structural shift toward integrated healthcare platforms combining AI, genomics, and regenerative medicine. This transition reflects movement from consumer wellness toward clinical prevention and early risk detection supported by institutional stakeholders.
Death prediction app launches ‘AI health concierge’
Death Clock has launched Life Lab, an AI-driven health concierge that integrates blood biomarker analysis with personalized preventive guidance to help users close the gap between their current and optimized projected lifespan. The service aggregates laboratory testing, medical records, and wearable data to identify actionable interventions across four major chronic disease categories.
Longevity.Technology unveils DLT – the intelligence platform for longevity
Longevity.Technology launched DLT, an AI-driven intelligence platform that aggregates data on over 600 longevity biotech companies, clinical assets, intellectual property, and partnerships into a queryable dataset. This addresses a fragmentation problem in longevity research and investment where critical market intelligence has been scattered across multiple sources.
Vitalist Bay 2026 set to spotlight longevity’s next phase
Vitalist Bay 2026 will convene researchers, investors, and founders in Berkeley for a concentrated four-day program emphasizing AI-driven drug discovery, biostasis, and longevity science. The event reflects the field's shift toward computational approaches while highlighting a persistent gap between scientific ambition and clinical validation.
Hospitals confront longevity’s quiet disruption
Hospital systems designed for acute crisis intervention face structural barriers to adopting longevity-focused prevention, requiring fundamental shifts in incentive structures, data integration, and measurement of success. The transition demands more than clinical protocol changes—it requires cultural reorientation toward longitudinal patient stewardship rather than episodic treatment.
The Longevity Show 80% sold out as inaugural gathers pace
The inaugural Longevity Show has reached 80% capacity in its partner floor with weeks remaining, signaling that longevity has transitioned from niche to mainstream market category. The event's broad ecosystem—spanning diagnostics, nutrition, fitness, therapeutics, and recovery—reflects how health optimization is increasingly understood as systemic rather than vertical.
Longevity Day at NFC Summit Lisbon Announces Speaker Lineup
Longevity Day at NFC Summit Lisbon will convene researchers, clinicians, founders, and investors on June 4, 2026, organizing speakers across three thematic tracks: ancestral wisdom, contemporary science, and frontier biotechnology. The event represents a structured approach to advancing longevity science through interdisciplinary dialogue.
Longevity market to hit $67b by 2035 due to rising aging concerns
The global longevity market is projected to grow from $27.61 billion in 2025 to $67.03 billion by 2035, driven by a shift from reactive disease treatment to preventive health monitoring and consumer-directed self-management. This expansion reflects a fundamental change in how aging is approached—not as an inevitable decline to manage, but as a process to optimize through early detection, biological measurement, and strategic intervention.
WELL Health owned Wisp launches longevity care suite
Wisp, a telehealth platform owned by WELL Health, launched a longevity care suite offering glutathione, NAD+, and low-dose naltrexone to support cellular energy, immune function, and biological repair in women. The initiative addresses gaps in aging care during perimenopause and menopause through clinician-guided, asynchronous consultations and personalized treatment adjustments.
Human Evidence Over Promise: Longevity Awards Redefine Success
The TOP 10 Longevity Breakthrough Awards 2026 establish a credibility filter for longevity interventions by requiring human clinical data and a realistic two-year pathway to implementation—not just mechanistic promise. This shift reflects a field-wide recognition that the gap between laboratory evidence and clinical utility determines whether discoveries actually reach patients.
Longevity public stocks are investable: here’s a DLT Chatbot guide
This article describes a data-driven approach to constructing longevity biotech investment portfolios by mapping public companies to the hallmarks of aging rather than disease labels. The mechanism-first framework enables investors to identify companies with broader pipeline optionality and reduced concentration risk across the fragmented longevity biotech landscape.
Defeating entropy: London takes on Longevity Levels 9 and 10
A London conference examines Longevity Levels 9 and 10—strategies that shift from slowing aging to replacing worn biological structures entirely, including whole brain emulation, organ replacement, and biostasis. These approaches represent a fundamental philosophical and technical departure from maintenance-focused longevity, treating the body as a modular system where critical components can be swapped rather than repaired.
First 100 speakers revealed for The Longevity Show
The Longevity Show's inaugural speaker lineup of 100 experts signals the maturation of longevity science from academic niche to mainstream economic and cultural priority. The event's dual-track structure—pairing geroscientists with clinicians, entrepreneurs, and consumer health voices—reflects a recognition that extending healthspan requires translation from discovery into sustained behavioral change across populations.